---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-002393"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:35:30.379252+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silexion shareholders approve 50M share increase, expanded equity plan, and 1-for-10 reverse split

## Summary
- Authorized shares increased from 9M to 59M via Memorandum Amendment effective May 5, 2026.
- Equity incentive plan evergreen provision raised from 5% of outstanding to pool of 10% fully diluted shares annually.
- Reverse stock split at 1-for-10 approved; can be reduced to maintain Nasdaq minimum public float.
- All three proposals passed with ~61% of votes in favor at reconvened meeting with 40.2% quorum.

## SEC filing metadata
- accession: 0001178913-26-002393
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/zk2635202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-002393
- JSON: https://secwatch.observer/filing/0001178913-26-002393.json
- Plain text: https://secwatch.observer/filing/0001178913-26-002393.txt

## Source-grounded claims
- claim_id: a720e5189c7c3dcf76ab27cf962c48097d204e39
  claim: Silexion Therapeutics Corp: Increase in authorized share capital from $121,500 divided into 9,000,000 ordinary shares to $796,500 divided into 59,000,000 ordinary shares (effective 2026-05-05).
  evidence_excerpt: At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.